Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2003

View Archived Issues

New CCR3 antagonists and their use described by Toray and Yamanouchi

AstraZeneca presents four novel series of CDK inhibitors

Preparation and use of neurotrophin inhibitors reported by JT team

New factor Xa inhibitors covered by Curacyte patent

BMS scientists discover novel CCR2 antagonists for asthma, multiple sclerosis, arthritis, etc.

Osteogenesis promoters and their use claimed by Yamanouchi

Human Genome Sciences acquires IHC diagnostic rights for TRAIL-R1 and TRAIL-R2

Yamanouchi receives approvable letter for Vesicare

Diversa and Medarex form antibody engineering strategic partnership

Favrille raises financing to support phase II and III trials of FavId for NHL

First NMDA receptor antagonist approved by FDA for Alzheimer's disease

Approval received to commence Canadian FluINsure field trial

Locus licenses novel gp41 crystal structure

Metabasis receives SBIR grant for efforts in hepatitis C

deCODE identifies genetic risk factors for heart attack

Speedel's new renin inhibitors show efficacy for hypertension, renal disease

Recent clinical development highlights at Tularik

Encouraging six-month results from phase II study of merimepodib in HCV

Pegasys approved in Japan

Pintex publishes data supporting Pin1 as a prognostic marker and therapeutic target in cancer

Japanese approval obtained for first-in-class antibiotic for community-acquired RTIs

Regulated hypothermia induced in rats by the neurotensin analogue NT-77

KIT as a potential target for postradiation sarcoma

Promising pharmacokinetic and safety data reported for a propofol prodrug in humans

Vasodilating effects of topical methyl nicotinate in diabetic patients

Comparison of CVT-3146 and adenosine as agents for pharmacological stress testing

AL-2512 as a potentially safer ocular antiinflammatory agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.